ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression

Fu, Rongdang; Jiang, Shaotao; Li, Jieyuan; Chen, Huanwei*; Zhang, Xiaohong*中山大学; 1
MEDICAL ONCOLOGY2020-3-12DOI: 10.1007/s12032-020-01350-4
62被引6阅读
引用收藏
分享

摘要

Lenvatinib is a long-awaited alternative to sorafenib for the first-line targeted therapy of patients with advanced hepatocellular carcinoma (HCC). However, resistance to lenvatinib has also become a major obstacle to improving the prognosis of HCC patients. The underlying molecular mechanisms contributing to lenvatinib resistance in HCC are largely unknown. HGF/c-MET axis activation is related to tumor progression and several hallmarks of cancer and is considered as the key contributor to drug resistance. In the present study, we focused on the role of the HGF/c-MET axis in mediating lenvatinib resistance in HCC cells. We showed that HGF reduced the antiproliferative, proapoptotic, and anti-invasive effects of lenvatinib on HCC cells with high c-MET expression but did not significantly affect HCC cells with low c-MET expression. The c-MET inhibitor PHA-665752 rescued HCC cells from HGF-induced lenvatinib resistance. Furthermore, HGF/c-MET activated the downstream PI3K/AKT and MAPK/ERK pathways and promoted epithelial-mesenchymal transition (EMT) in HCC cells. Collectively, our results suggested that combining lenvatinib treatment with a c-MET inhibitor may improve its systemic therapeutic efficacy in HCC patients with high c-MET expression.

学科与关键词

关键词
LenvatinibHGFc-METHepatocellular carcinomaResistance
相关
加载中…
  • MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met
    Xu, Xin; Jiang, Wenjing; Han, Peng; Zhang, Jingyan; Tong, Liquan*; Sun, Xueying*Journal of Hepatocellular Carcinoma, 2022, 9: 113-126.被引 13
  • Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma
    Huang, Shanzhou; Ma, Zuyi; Zhou, Qi; Wang, Aimei; Gong, Yuanfeng; Li, Zhenchong; Wang, Shujie; Yan, Qian; Wang, Dongping*; Hou, Baohua*; Zhang, Chuanzhao*International Journal of Biological Sciences, 2022, 18(11): 4357-4371.被引 15
  • Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy
    Zhang, Yuxin; Zhang, Yujie; Tao, Haisu; Zhu, Jinghan; Lu, Yuanxiang; Cheng, Fangling; Xiong, Yixiao; Liu, Junjie; Cai, Guangzhen; Zhang, Zhanguo*; Liang, Huifang*; Chen, Yifa*; Zhang, Wanguang*Cancer Letters, 2023, 576: 216405.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
MEDICAL ONCOLOGY
发表日期
2020-03-12
卷期
第 37 卷, 第 4 期
页码
24
DOI
10.1007/s12032-020-01350-4
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
4区
成果收录
SCIE
资助标注
Medical Science and Technology Research Fund of Guangdong Province, China [A2017387]

作者

  • F

    Fu, Rongdang (第一作者)

    sun yat sen univ

  • J

    Jiang, Shaotao

    1 · 2

查看全部 5 位作者收起作者
  • L

    Li, Jieyuan

    sun yat sen univ

  • C

    Chen, Huanwei (通讯)

    sun yat sen univ

  • Z

    Zhang, Xiaohong (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417